High-dose Lipitor cuts CV risk 27% in bypass patients

	Tweet

World drug giant Pfizer’s Lipitor (atorvastatin calcium) 80mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 27% in patients with heart disease who had previous coronary bypass surgery compared with subjects taking the 10mg dose of the drug. This analysis, designed and completed following the closure of the five-year Treating to New Targets study, was published in a recent issue of the Journal of the American College of Cardiology.

Intensive Lipitor therapy also provided a significant 30% reduction in the need for either repeat coronary bypass surgery or Angioplasty , another type of interventional heart surgery, compared with Lipitor 10mg, the firm noted.

Each year in the USA, approximately 470,000 bypass surgeries are performed on 270,000 people. Patients in the TNT study who had undergone previous bypass surgery had a much higher likelihood of cardiovascular events than those who did not. This especially high-risk population tends to be under-treated with lipid-lowering therapy, Pfizer stated.

Marketletter - May. 26, 2008

RELATED STORIES:
Scientists turn skin cells into beating heart muscle   Too many people get angioplasties, study suggests   New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA   Heart Damage After Chemo Linked to Stress in Cardiac Cells   What’s good or bad for the heart, may be the same for the brain   Warfarin in Heart Failure   Increased Sudden Cardiac Death Rate Among HIV Patients   Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease   Lack of basic evidence hampering prevention of sudden heart attacks in sport   Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study   Heart attack patients taken to PCI hospitals first treated faster   Cameron Health’s under-skin ICD safe, effective

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]